Investigating radiotherapy’s impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab

Table 1 Clinical efficacy in the two groups, n (%)

Group	CR	PR	SD	PD	Disease control rate	Total effectiveness
Bevacizumab + radiotherapy group (n = 35)	8 (22.86)	11 (31.43)	9 (25.71)	7 (20.00)	28 (80.00)	19 (54.29)
Bevacizumab only group (n = 35)	3 (8.57)	7 (20.00)	11 (31.43)	14 (40.00)	21 (60.00)	10 (28.57)
χ2	-	-	-	-	-	4.769
P value	-	-	-	-	-	0.029

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 2 Incidence of intestinal perforation, n (%)

Group	Incidence of intestinal perforation
Bevacizumab + radiotherapy group (n = 35)	4 (11.43)
Bevacizumab only group (n = 35)	0 (0.00)
χ2	4.242
P value	0.038

Table 3 Comparison of survival between the two groups, n (%)

Group	OS	PFS
Bevacizumab + radiotherapy group (n = 35)	23 (76.67)	22 (73.33)
Bevacizumab only group (n = 35)	17 (56.67)	17 (56.67)
χ2	7.822	10.229
P value	0.005	0.001

OS: Overall survival; PFS: Progression-free survival.

Table 4 Serum tumor marker levels in the two groups, mean ± SD

Group	CA125 (kU/L)		CA153 (U/mL)		CA199 (U/mL)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Bevacizumab + radiotherapy group (n = 35)	31.44 ± 52.33	6.29 ± 1.23a	18.95 ± 29.55	30.21 ± 3.66a	50.12 ± 65.88	6.45 ± 1.12a
Bevacizumab only group (n = 35)	34.73 ± 53.26	7.36 ± 1.42a	17.53 ± 11.14	35.26 ± 3.85a	51.33 ± 72.72	9.10 ± 1.32a
t	0.260	4.474	0.265	7.194	0.073	12.438
P value	0.795	< 0.001	0.792	< 0.001	0.942	< 0.001

^aP < 0.05 vs the group before treatment.

CA: Carbohydrate antigen.